DM3-SMe
| Code | Size | Price |
|---|
| TAR-T11057-100mg | 100mg | £4,340.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
DM3-SMe is a maytansine derivative and tubulin inhibitor. It is a cytotoxic part of antibody-drug conjugates (ADCs) and can bind to antibodies via disulfide bonds or stable thioether bonds. DM3-SMe has high cytotoxic activity in vitro with IC50 of 0.0011 nM.
CAS:
796073-70-6
Formula:
C38H54ClN3O10S2
Molecular Weight:
812.43
Purity:
0.98
SMILES:
[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)C=C/C=C(C)Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCC(C)SSC)[C@]1(C)O[C@H]1[C@@H]2C
References
1. Chen H, et al. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2017 Aug 1;22(8).
2. Yuliang Zhaoet al. Biomedical Nanomaterials. 2016-?Science.